SCHEMBL6712685

SCHEMBL6712685

COc1ccccc1CNCc1ccccc1-c1noc2ccccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
CYP3A4 P08684 2/20 0.47
CYP2D6 P10635 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
CHRM2 P08172 13/20 0.46
BCHE P06276 5/20 0.46
ACHE P22303 5/20 0.46
CHRM4 P08173 5/20 0.46
CHRM5 P08912 5/20 0.46
CHRM1 P11229 5/20 0.46
CHRM3 P20309 5/20 0.46
GRIN1 Q05586 4/20 0.46
GRIN2A Q12879 4/20 0.46
RECQL P46063 2/20 0.46
TP53 P04637 1/20 0.46
TSHR P16473 1/20 0.46
THPO P40225 1/20 0.46
NPC1 O15118 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6711210 0.88 ESR1 (0.49) CYP2D6TSHRNPC1
SCHEMBL2479131 0.81 PKM (0.46) CYP2D6CYP1A2NPC1MEN1MAPT
Hydrochloric Acid SCHEMBL6710202 0.78 ESR1 (0.45) KDM4ECYP3A4NPC1MAPT
SCHEMBL8528744 0.76 ESR1 (0.41) ALDH1A1NPC1SMN1; SMN2TDP1
SCHEMBL8529936 0.75 MPO (0.51) BCHEMAPTSMN1; SMN2
Hydrochloric Acid SCHEMBL6710240 0.75 ESR1 (0.40) ALDH1A1NPC1SMN1; SMN2TDP1
SCHEMBL5695121 0.75 ALDH1A1 (0.79) KDM4EALDH1A1CYP3A4CYP2D6CHRM2
Hydrochloric Acid SCHEMBL7703819 0.74 MPO (0.50) CYP3A4CYP2D6CYP2C19BCHEPOLB
Hydrochloric Acid SCHEMBL6758050 0.74 HTT (0.52) ALDH1A1CYP3A4CYP2D6CYP1A2CYP2C19
SCHEMBL6711049 0.73 ESR1 (0.56)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040229910-A1 Therapeutic compounds N.V. ORGANON (NL) 2004-11-18 US disclosed
EP-0898566-B1 SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION AKZO NOBEL NV (NL) 2002-11-06 EP disclosed
US-20020037885-A1 Therapeutic compounds DIJCKS FREDERICUS ANTONIUS (NL) 2002-03-28 US disclosed
US-6313139-B1 ADMINISTERING BENZYLAMINE DERIVATIVE FOR THERAPY OF PSYCHIATRIC DISORDER IN MAMMALS AKZO NOBEL N. V. (NL) 2001-11-06 US disclosed
US-6080773-A USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS AKZO NOBEL, N.V. (NL) 2000-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229910-A1 Therapeutic compounds BDNF, PNMT, SLC18A2 KDM4E 1272/4885ALDH1A1 964/4885CYP3A4 1294/4885
US-20020037885-A1 Therapeutic compounds BDNF, PNMT, SLC18A2 KDM4E 1272/4885ALDH1A1 964/4885CYP3A4 1294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.